Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Figure 1

Consort diagram: Among 285 eligible patients 143 were randomized in group A (XELIRI-Bev) and 142 in group B (FOLFIRI-Bev). In group A 88 (61%) and in group B 89 (63%) of the patients completed treatment. Reasons of discontinuation were death, non-fatal toxicity, disease progression and doctor’s or patient’s decision. Discontinuation rates did not differ between the two groups (p = 0.80).

Back to article page